WO2008088804A1 - Genetic analyses predictive of asthma - Google Patents
Genetic analyses predictive of asthma Download PDFInfo
- Publication number
- WO2008088804A1 WO2008088804A1 PCT/US2008/000524 US2008000524W WO2008088804A1 WO 2008088804 A1 WO2008088804 A1 WO 2008088804A1 US 2008000524 W US2008000524 W US 2008000524W WO 2008088804 A1 WO2008088804 A1 WO 2008088804A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sequence
- seq
- single nucleotide
- nucleotide polymorphism
- exactly matching
- Prior art date
Links
- 208000006673 asthma Diseases 0.000 title claims abstract description 79
- 238000012252 genetic analysis Methods 0.000 title description 2
- 101100153387 Homo sapiens TLR7 gene Proteins 0.000 claims abstract description 11
- 101150033086 TLR7 gene Proteins 0.000 claims abstract description 11
- 101150052909 CCL2 gene Proteins 0.000 claims abstract description 8
- 239000002773 nucleotide Substances 0.000 claims description 95
- 125000003729 nucleotide group Chemical group 0.000 claims description 95
- 108091034117 Oligonucleotide Proteins 0.000 claims description 40
- 108090000623 proteins and genes Proteins 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 22
- 101150084750 1 gene Proteins 0.000 claims description 12
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 238000003752 polymerase chain reaction Methods 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 238000000018 DNA microarray Methods 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 239000004677 Nylon Substances 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- 229920001778 nylon Polymers 0.000 claims description 3
- 239000004033 plastic Substances 0.000 claims description 3
- 238000012408 PCR amplification Methods 0.000 claims 1
- 238000012300 Sequence Analysis Methods 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 101150020847 CCL11 gene Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 22
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 18
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 13
- 230000000875 corresponding effect Effects 0.000 description 12
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 8
- 230000003993 interaction Effects 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 238000002493 microarray Methods 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 102000054766 genetic haplotypes Human genes 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 238000010200 validation analysis Methods 0.000 description 4
- -1 0.1-0.5x SSC Chemical class 0.000 description 3
- 208000019693 Lung disease Diseases 0.000 description 3
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 3
- 102000002689 Toll-like receptor Human genes 0.000 description 3
- 108020000411 Toll-like receptor Proteins 0.000 description 3
- 230000010085 airway hyperresponsiveness Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000003205 genotyping method Methods 0.000 description 3
- 102000054765 polymorphisms of proteins Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 206010003645 Atopy Diseases 0.000 description 2
- 102100023688 Eotaxin Human genes 0.000 description 2
- 101710139422 Eotaxin Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229940125388 beta agonist Drugs 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000013211 curve analysis Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000037874 Asthma exacerbation Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010040471 CC Chemokines Proteins 0.000 description 1
- 102000001902 CC Chemokines Human genes 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 101100495070 Homo sapiens CCL2 gene Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 229940127225 asthma medication Drugs 0.000 description 1
- 238000013476 bayesian approach Methods 0.000 description 1
- 238000013398 bayesian method Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000000588 effect on asthma Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 230000002922 epistatic effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 102000046768 human CCL2 Human genes 0.000 description 1
- 102000045715 human TLR7 Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 238000009607 mammography Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 1
- 229960002329 methacholine Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 238000009424 underpinning Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Definitions
- the microarray may also include at least one oligonucleotide that: a) has a sequence exactly matching a corresponding sequence in SEQ ID NO: 10 and includes the single nucleotide polymorphism of rsl 12944; b) has a sequence exactly matching a corresponding sequence in SEQ ID NO: 11 and includes the single nucleotide polymorphism of rsl7735961; or c) has a sequence exactly matching a corresponding sequence in SEQ ID NO: 12 and includes the single nucleotide polymorphism of rs4795895.
- microarrays may include an oligonucleotide exactly matching a corresponding sequence in SEQ ID NO: 13 and which includes the single nucleotide polymorphism of rs4586.
- the invention also encompasses kits for amplifying nucleic acids using the polymerase chain reaction (PCR) in which there are pairs of primers for amplifying regions of the TLR7, CCLl 1 and CCL2 genes. These primer pairs may be designed to specifically amplify regions that can be used to determine if the SNPs shown in Figure 7 are present.
- PCR polymerase chain reaction
- the seven SNPs that were associated with asthma status in our predictive model were then genotyped using either of the above techniques (Sequenom or Taqman) in the EMGB, Coriell, Sepracor, and independent NHS control subjects to provide independent model validation.
Abstract
The present invention is directed to genetic sequence variations that can be used to predict whether a person will develop asthma. Disease is likely to occur if certain polymorphic forms the CCL11 gene, the CCL2 gene and the TLR7 gene are present.
Description
Genetic Analyses Predictive of Asthma
Cross Reference to Related Applications
The present application claims priority to, and the benefit of, United States provisional application 60/880,709, filed on January 17, 2007, the contents of which is hereby incorporated by reference in its entirety.
Statement of Government Funding
The United States Government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others under reasonable terms as provided for by the terms of NIH Grant No. HL067664, awarded by the Department of Health and Human Services.
Field of the Invention The present invention is directed to genetic assays for predicting if a subject will develop asthma. Individuals with a combination of certain polymorphic forms of the CCLl 1 gene, the CCL2 gene and TLR7 gene have a high likelihood of becoming asthmatic.
Background of the Invention Asthma is a complex disease affecting an estimated 20.5 million Americans and costing the US approximately $16.1 billion annually in health care expenses.1 Models for predicting adult asthma proposed to date have been constructed using clinical characteristics. Measures that have been found to be significant independent predictors include lung function, airway hyperresponsiveness, atopy, parental history of asthma, and female gender.5' 6 Although a parental history has been found to be a predictor of asthma, ■ genetic data have not been used to investigate this phenomenon.5
Asthma results from the complex interaction of multiple genetic and environmental factors, which causes its phenotypic expression to vary across individuals. In genetic association studies, over 100 genes have been associated with asthma- and atopy-related phenotypes.7 Of these genes, 25 have been associated in six or more populations and 54 have been associated in two to five populations. None of the single-gene association studies to date has developed a reliable predictive model of asthma. Because asthma is a
prototypical complex disease, traditional association studies, which attempt to find single gene associations or assume an additive model of gene interaction are inherently limited in finding complex genetic interactions that may be predictive of asthma.
Summary of the Invention
The present invention is based upon a novel multivariate method of analysis called Bayesian networks, which are multivariate models able to account for simultaneous associations and interactions among genes to predict asthma status of subjects based on their genotype. Bayesian networks have been successfully used to study gene expression data, protein-protein interactions,9 and pedigree analysis.10 They also have been used to model the multigenic association and predict the occurrence of stroke in sickle cell anemia patients, demonstrating the suitability of such networks for understanding the genetic basis of complex diseases and predicting a clinical phenotype.11 Notwithstanding its recent introduction, the Bayesian network approach is already regarded as an emerging paradigm for the analysis of complex traits.12'13 Using this approach SNPs were identified that are, in combination, present in patients that are highly susceptible to the development of asthma.
In its first aspect, the invention is directed to a method for diagnostically assessing if a subject is at high risk of developing asthma by determining the polymorphic forms of at least three genes: i) the TLR7 gene (see Figure 1, SEQ ID NO:1); ii) the CCLl 1 gene (see Figure 3, SEQ ID NO:3); and iii) the CCL2 gene (see Figure 5, SEQ ID NO:5). The term "is at high risk" means that the subject is among a group of people where more than 80% will develop asthma. Among the specific single nucleotide polymorphisms that have been, in combination, found to be characteristic of this group are the ones shown in Figure 7. These include: rsl79019 (SEQ ID NO:7); rsl79020 (SEQ ID NO:8); rsl79017 (SEQ ID NO:9); rsl 129844 (SEQ ID NO: 10); rsl7735961 (SEQ ID NO:11); rs4795895 (SEQ ID NO:12); and rs4586 (SEQ ID NO: 13).
The determination of gene sequences may be carried out using any method known in the art. For example, regions of the TLR7, CCLl 1 and CCL2 genes may be amplified using the polymerase chain reaction and then sequenced. Alternatively, a DNA microarray may be used in which oligonucleotides that hybridize to specific polymeric forms of genes under conditions of high stringency (e.g., 0.1-0.5x SSC, 500C - 68°C) are immobilized on a glass,
plastic or nylon support. In general, the oligonucleotides should be 20-500 nucleotides in length and should have sequences that hybridize with TLR7, CCLl 1 and CCL2. For example, the microarray may include: a) at least one oligonucleotide with a sequence that matches exactly a corresponding sequence in SEQ ID NO:1 except that one nucleotide is replaced with a different nucleotide, a nucleotide is deleted or a nucleotide is added; b) at least one oligonucleotide with a sequence that matches exactly a corresponding sequence in
SEQ ID NO:3 but in which one nucleotide is replaced with a different nucleotide, a nucleotide is deleted or a nucleotide is added; and c) at least one oligonucleotide has a i sequence that matches exactly a corresponding sequence in SEQ ID NO:5 but in which one nucleotide is replaced with a different nucleotide, a nucleotide is deleted or a nucleotide is added.
In a preferred embodiment the microarray has oligonucleotides that are 20-250 nucleotides in length and there is at least one oligonucleotide that a) has a sequence exactly matching a corresponding sequence in SEQ ID NO:7 and includes the single nucleotide polymorphism of rs 179019; b) has a sequence exactly matching a corresponding sequence in SEQ ID NO:8 and includes the single nucleotide polymorphism of rsl79017; or c) has a sequence exactly matching a corresponding sequence in SEQ ID NO:9 and includes the single nucleotide polymorphism of rs 179017. The microarray may also include at least one oligonucleotide that: a) has a sequence exactly matching a corresponding sequence in SEQ ID NO: 10 and includes the single nucleotide polymorphism of rsl 12944; b) has a sequence exactly matching a corresponding sequence in SEQ ID NO: 11 and includes the single nucleotide polymorphism of rsl7735961; or c) has a sequence exactly matching a corresponding sequence in SEQ ID NO: 12 and includes the single nucleotide polymorphism of rs4795895. In addition, microarrays may include an oligonucleotide exactly matching a corresponding sequence in SEQ ID NO: 13 and which includes the single nucleotide polymorphism of rs4586.
The invention also encompasses kits for amplifying nucleic acids using the polymerase chain reaction (PCR) in which there are pairs of primers for amplifying regions of the TLR7, CCLl 1 and CCL2 genes. These primer pairs may be designed to specifically amplify regions that can be used to determine if the SNPs shown in Figure 7 are present. Thus, for detecting the form of the TLR7 gene present, a kit may include: a) an oligonucleotide primer pair where one primer has a sequence exactly matching a sequence
in SEQ ID NO:7 and which lies at least partially 51 to the single nucleotide polymorphism of rs 179019 and a second that has a sequence exactly matching a sequence in SEQ ID NO: 7 and which lies at least partially 3' to the single nucleotide polymorphism of rsl79019; b) an oligonucleotide primer pair where one primer has a sequence exactly matching a sequence in SEQ ID NO:8 and which lies at least partially 5' to the single nucleotide polymorphism of rs 179020 and a second primer with a sequence exactly matching a sequence in SEQ ID NO:8 and which lies at least partially 3' to the single nucleotide polymorphism of rs 179020; and/or c) an oligonucleotide primer pair where one primer has a sequence exactly matching a sequence in SEQ ID NO:9 and which lies at least partially 5' to the single nucleotide polymorphism of rs 179017 and a second primer that has a sequence exactly matching a sequence in SEQ ID NO:9 and which lies at least partially 3' to the single nucleotide polymorphism of rs 179017.
The kit may also include primer pairs for detecting the polymorphic form of the CCLI l gene such as: a) an oligonucleotide primer pair where one primer has a sequence exactly matching a sequence in SEQ ID NO: 10 and which lies at least partially 5' to the single nucleotide polymorphism of rsl 129844 and a second primer has a sequence exactly matching a sequence in SEQ ID NO: 10 and which lies at least partially 3' to the single nucleotide polymorphism of rsl 129844; b) an oligonucleotide primer pair where one primer has a sequence exactly matching a sequence in SEQ ID NO: 11 and which lies at least partially 5' to the single nucleotide polymorphism of rsl7735961 and a second primer that has a sequence exactly matching a sequence in SEQ ID NO: 11 and which lies at least partially 3' to the single nucleotide polymorphism of rsl7735961; and/or c) an oligonucleotide primer pair where one primer has a sequence exactly matching a sequence in SEQ ID NO: 12 and which lies at least partially 5' to the single nucleotide polymorphism of rs4795895 and a second primer has a sequence exactly matching a sequence in SEQ ID NO: 12 and which lies at least partially 3' to the single nucleotide polymorphism of rs4795895. The kit can also include primers that amplify regions of the CCL2 gene which may have polymorphisms. For example, it may have a pair of primers where one has a sequence exactly matching a sequence in SEQ ID NO: 13 and which lies at least partially 5' to the single nucleotide polymorphism of rs4586 and a second has a sequence exactly matching a sequence in SEQ ID NO: 13 and which lies at least partially 3' to the single
nucleotide polymorphism of rs4586. In all cases, the primers should be at least 14 nucleotides in length and, in general not longer than about 100 or 200 nucleotides in total.
An association between nucleic acid sequences and the likelihood of developing asthma may also be made at the protein level. Thus, a determination may be made as to whether a subject is at high risk of developing asthma based upon the amino acid sequence of at least: i)the TLR7 gene product (SEQ ID NO:2); ii) the CCLl 1 gene product (SEQ ID
NO:4); and iii) the CCL2 gene product (SEQ ID NO:6). Analysis may be carried out using any method known in the art but immunoassays utilizing antibodies capable of detecting different forms of proteins are generally preferred. The assays may take the form of
ELISAs, radioimmunoassay or arrays in which antibodies or proteins are immobilized on a plate, or slide. Techniques such as SELDI-MS (surface enhanced laser desorption/ionization mass spectrometry) may also prove useful.
Brief Description of the Drawings
Figure 1 : Human TLR7 Reference Nucleotide Sequence. The sequence shown in the figure is designated herein as SEQ ID NO: 1.
Figure 2: Human TLR7 Gene Product. The amino acid sequence shown in the figure is designated herein as SEQ ID NO:2.
Figure 3: Human CCLI l Reference Nucleotide Sequence. The sequence shown in the figure is designated herein as SEQ ID NO:3.
Figure 4: Human CCLl 1 Gene Product. The amino acid sequence shown in the figure is designated herein as SEQ ID NO:4.
Figure 5: Human CCL2 Reference Nucleotide Sequence. The sequence shown in the figure is designated herein as SEQ ID NO:5.
Figure 6: Human CCL2 Gene Product. The amino acid sequence shown in the figure is designated herein as SEQ ID NO:6.
Figure 7: Seven SNPs Characteristic of Asthma: The sequences shown in the figure have the following sequence identifiers:
TLR7: rsl79019: SEQ ID NO:7 rsl 79020: SEQ ID NO:8 rsl 79017: SEQ ID NO:9
CCLI l : rsl 129844: SEQ ID NO: 10 ral7735961 : SEQ ID NO: 11 rs4795895: SEQ ID NO: 12 CCL2 rs4586 SEQ ID NO:13
Description of the Invention
The present invention is based upon an association between sequence variations occurring in a combination of three genes and the subsequent development of asthma, hi particular, the genes are the human TLR7 gene (Gene ID 51284, see NCBI sequence NM_016562 and NP_057646, see also, Morris, et al, FASEB J. 20(12) :2153-2155 (2006)); the human CCLl 1 gene (Gene ID 6356, see NCBI sequence NM 002986 and NP 002977, see also, Mir, et al, Parasite Immunol. 2^:397-400 (2006)); and CCL2 (see NCBI sequence NM 002982 and NP 002973, see also, Lee, et al, J. Gen. Virol. 87φtl 2):3623-3630 (2006)).
Methods for genotyping individuals to determine the forms of TLR7, CCLl 1 and CCL2 present are well established in the art. Typically these methods involve a step in which relevant sequences are amplified by PCR. The "Examples" section below provides guidance concerning appropriate procedures but it will be recognized by those of skill in the art that alternatives can also be used. All of the gene sequences required for selecting primers are known and reagents for performing amplifications are commercially available.
Microarrays may also be used in looking for new SNPs and in detecting those that have already been associated with the development of asthma. New SNPs may be looked for by immobilizing sequences that match the known sequences for TLR7, CCLl 1 and CCL2 but in which a single nucleotide is altered. Hybridizations carried out under conditions of high stringency (low salt, e.g., 0.1-0.5x SSC, and high temperature , e.g., 500C - 68°C) may then be used to determine whether a corresponding sequence exists in a
sample. Correlations between different polymorphisms and the subsequent development of asthma may then be arrived at using the methodology described herein. Plates with oligonucleotides hybridizing to one or more (preferably all) of the seven SNPs described as being associated with asthma herein may also be used and will be of particular value. Samples that indicate that the TLR7, CCLl 1 and CCL2 genes all have one of the SNPs are an indication that the subject from which they are derived is at very high risk for developing asthma.
The findings presented herein suggest that other alterations in TLR7, CCLI l and CCL2, i.e., beyond the seven SNPs shown in figure 7 may also lead to an increased risk of developing asthma. As discussed above, these changes may be determined using analyses of nucleic acids. However, an examination of the proteins made by these genes, both in terms of amino acid sequence and the amount of protein produced, may also be useful.
The identification of individuals likely to develop asthma may lead to earlier diagnosis, earlier treatment and to counseling regarding life style. In addition, the identification of specific genes that together lead to asthma may suggest new areas for research into the causes and treatment of this disease.
Examples
The present example describes the construction of a Bayesian network using genotypic data from cases with asthma and non-asthmatic controls from the Nurses' Health
Study (NHS), one of the largest prospective studies of risk factors for major chronic diseases in women,14 that effectively predicts asthma status in subjects from two independent populations.
I. Methods
Training Study
DNA was obtained from incident cases of adult asthma (n=428) and non-asthmatic controls (n=422) from the NHS. Cases were white female lifelong nonsmoking adults with a new self-reported physician diagnosis of asthma, and age-matched controls were white female lifelong nonsmoking adults who did not have a self-reported physician diagnosis of
asthma or other pulmonary disease. Self-reported health outcomes in the NHS, including asthma, have been found to be reliable indicators of true disease15.
Independent Study 1 DNA samples from 21 white asthmatic individuals (16 male, 5 female) were obtained from the Environmental Medicine Genome Bank (EMGB), a repository consisting of army recruits from across the country undergoing basic training. DNA samples from 44 apparently healthy and unrelated self-reported European American (n=21; 10 male, 11 female) and African American (n=23; 11 male, 12 female) adults were obtained from the Coriell Institute for Medical Research (Camden, NJ). Independent Study 2
DNA samples were obtained from 168 unrelated adults originally recruited for an asthma medication trial in the United States. Subjects were 80 male and 88 female white non-smoking asthmatic patients, who were diagnosed according to American Thoracic Society criteria.16 Asthma diagnosis was confirmed by reversible airway obstruction (of at least 15 percent) by beta-agonists or methacholine challenge testing. The percent predicted FEVl values of all patients were 40 to 85 percent of normal after at least eight hours without inhaling beta-agonists. Further details about this population have been published previously.17 An independent cohort of 69 controls was collected from the NHS solely for the predictive validation of the model built from the training study. These controls were white female lifelong nonsmoking adults who did not have a self-reported physician diagnosis of asthma or other pulmonary disease.
Informed consent was obtained from all participants. The study was approved by the Institutional Review Board of the Brigham and Women's Hospital.
Genotypinp
Sixty-six candidate genes were identified as likely to be involved in asthma susceptibility by the Innate Immunity in Heart, Lung, and Blood Disease Programs for Genomic Applications (IIPGA).19 Single nucleotide polymorphism (SNP) selection was performed such that a small set of tagging SNPs distinguished the common haplotypes of the genes of interest. Haplotypes were inferred using the Bayesian method implemented in PHASE, and SNPs that distinguished the most common haplotypes were identified using
the BEST algorithm.21 Rare SNPs (minor allele frequency less than five percent) were considered for genotyping if the SNP led to a nonconservative amino acid change, implying potential functional significance. Genotyping of the haplotype tagging SNPs (htSNPs) and the nonsynonymous SNPs was performed in the NHS subjects using either multiplexed single-base extension with a Sequenom Mass Spectrometry MALDI-TOF system (SEQUENOM, San Diego, CA) or Taqman real-time PCR with an ABI Prism 7900 machine (Applied Biosystems, Foster City, CA). Approximately 10 percent of samples were genotyped twice as part of standard quality control procedures.
The seven SNPs that were associated with asthma status in our predictive model were then genotyped using either of the above techniques (Sequenom or Taqman) in the EMGB, Coriell, Sepracor, and independent NHS control subjects to provide independent model validation.
Predictive Model Construction
Following the method proposed by Sebastiani et al.,u a Bayesian network was constructed from a set of 850 subjects (428 cases, 422 controls) genotyped at 226 SNPs in 66 genes using Bayesware Discoverer (http://bayesware.com), a computer program that implements a common Bayesian approach to identify the most probable network of dependency from a dataset.22 To find such a network, the program explores a space of different network models, scores each model by its posterior probability given the data, and returns the model with maximum posterior probability.
Predictive Validation The predictive validation of the model built with the training study was assessed by predicting asthma status in each subject of the two independent studies and comparing the predicted risk of asthma to the actual diagnosis of the subject. The probability of asthma given the genotype of an individual subject was calculated using the clique algorithm implemented in Bayesware Discoverer as described previously. ' ' The performance of the predictive model was evaluated by calculating receiver operator characteristic (ROC) curves. Convex hulls were estimated for each ROC curve using the Qhull algorithm23 as implemented in Matlab (Mathworks, Natick, MA). The area under the ROC curve convex hull (AURC) was obtained using the trapezoidal rule.24 The predictive accuracy of the
network derived from the original 850 NHS subjects was tested with two independent study populations: (1) EMGB asthma cases (n=21) and Coriell controls (n=44), and (2) Sepracor asthma cases (n=168) and NHS controls (n=69).
II. Results
A Bayesian network was created from SNPs from 66 genes genotyped in 850 NHS subjects (428 asthma cases, 422 controls). The network found that seven SNPs in the TLR7, CCLI l, and CCL2 genes modulate the risk of asthma. Of these SNPs, four have a direct effect on asthma status (CCLl l_005208/rs3744508, TLR7_007154/rsl79019, CCLl l_004654/rsl7735961, and TLR7_007042/rs 179020), and three are indirectly associated through the others (CCLl 1 003760/rs4795895, CCL2_005972/rs4586, and TLR7_010982/rsl79017). CCLI l and TLR7 are the two genes that are directly related to asthma status. CCL2 is related to asthma status through CCLl 1. Remaining SNPs that were linked to one another in separate networks mostly correspond to SNPs of the same gene. No TLR7, CCLl 1 , or CCL2 SNPs were linked to SNPs of other genes and one TLR7 SNP was not linked to any other node in the network.
The accuracy of this seven-SNP network was tested by using it to predict asthma status in two independent adult populations. The first group, consisting of 21 cases with asthma and 44 controls, was very well differentiated into cases and controls and had an AURC of 0.95. The second independent population, consisting of 168 cases with asthma and 69 controls, was well differentiated into cases and controls by the network with an AURC of 0.82. Although the initial model was constructed using data from females only, tests on the independent study populations, which included male and female cases and controls and black and white controls, were still effective in differentiating cases from controls.
The fundamental role of epistatic interactions was assessed by comparing the ability of each individual SNP to predict asthma to that of using all SNPs. Our results show that these SNPs individually fail to accurately predict asthma status, as demonstrated by the corresponding AURC values of 0.5, the predictive accuracy achieved by random chance.
The two SNPs that are nearest the asthma status node in the network have a slightly
increased accuracy, but this accuracy is far lower than that resulting from using data of all seven SNPs.
III. Discussion The present example demonstrates that a multivariate SNP model effectively predicts asthma status in subjects from two independent populations. A predictive model was constructed from genotypic data from white female NHS data, which found that seven SNPs from three genes out of 226 SNPs from 66 genes modulate the risk of asthma. The predictive ability of this model was tested on two independent study populations, including both male and female subjects and black and white controls. These results show that our predictive model is accurate in subjects of either gender and is robust to some measure of racial variability.
The CCLI l and TLR7 genes, which are directly related to asthma status in our model, are known to have a role in asthma-related phenotypes. The product of the CCLl 1 gene, eotaxin, is a C-C chemokine involved in the recruitment of peripheral blood eosinophils into the lung during acute allergic inflammation,25 has been found at high levels in bronchoalveolar lavage fluid of asthmatic individuals,26 and is correlated with asthma severity27 and airway hyperresponsiveness.28 TLR7 is a toll-like receptor (TLR) that specifically recognizes viral single-stranded RNA.29 The activation of TLRs leads to the activation of cytokines and other genes that mediate immune responses.30 Consistent with the involvement of TLR7 in asthma, a study of mice treated with a TLR7 ligand prevented allergen-induced airway hyperresponsiveness and eosinophilia, and led to decreased IgE levels.31 The Bayesian network suggests a biological mechanism by which both TLR7 and CCLl 1 mediate asthma. Based on what is known about both genes, one possible hypothesis is that viral infection with rhinoviruses, common single stranded RNA viruses that are frequently associated with asthma exacerbations in adults,32 may stimulate TLR7 to activate an eosinophilic inflammatory response that is mediated by CCLl 1.
We are not aware of any published study to date that has reported on the association of TLR7 variants with asthma or a related phenotype. Previous studies have investigated the association of individual CCLl 1 variants with asthma and found discrepant results. A recent family-based study found that one CCLl 1 SNP is associated with asthma among black
subjects, and other CLLI l variants are associated with IgE levels among black and white subjects.33 However, five case-control studies have found no association between CCLl 1 variants and asthma,34"38 although some of these studies did find an association with related phenotypes.36'38 The inconsistency among the results of these single-SNP association studies may be due to the inadequacy of traditional analytic measures to find associations when a gene variant has a biological effect in the context of other genes. Multivariate methods able to account for the interactions underpinning complex biological processes, such as the one used in this example, increase the ability to find association of SNPs to a phenotype because effects that are modulated through complex interactions can be found.
ROC curve analysis suggested that, in the first independent population, a predictive model based upon the sequences discussed above is ideally sensitive (100 percent) and highly specific (84 percent) at its most accurate threshold. By comparison, ROC curve analysis for the second independent population, suggested the model is highly sensitive (95/90/87 percent) for thresholds at which the specificity is lower (54/57/60 percent).
References
1. American Lung Association. Trends in Asthma Morbidity and Mortality. New York, NY: Epidemiology and Statistics Unit, Research and Program Services, American Lung Association; 2006.
2. Schatz M, Clark S, Camargo CA, Jr. Sex differences in the presentation and course of asthma hospitalizations. Chest 2006;129(l):50-5.
3. Moorman JE, Mannino DM. Increasing U.S. asthma mortality rates: who is really dying? J Asthma 2001;38(l):65-71. 4. Barnes N. Most difficult asthma originates primarily in adult life. Paediatr Respir Rev 2006;7(2):141-4.
5. Jenkins MA, Hopper JL, Bowes G, Carlin JB, Flander LB, Giles GG. Factors in childhood as predictors of asthma in adult life. Bmj 1994;309(6947):90-3.
6. Toelle BG, Xuan W, Peat JK, Marks GB. Childhood factors that predict asthma in young adulthood. Eur Respir J 2004;23(l):66-70.
7. Ober C, Hoffjan S. Asthma genetics 2006: the long and winding road to gene discovery. Genes Immun 2006;7(2):95-100.
8. Friedman N. Inferring cellular networks using probabilistic graphical models. Science 2004;303(5659):799-805. 9. Jansen R, Yu H, Greenbaum D, et al. A Bayesian networks approach for predicting protein-protein interactions from genomic data. Science 2003;302(5644):449-53.
10. Lauritzen S, Sheehan N. Graphical Models for Genetic Analysis. Statist Sci 2004; 18:489-514.
11. Sebastiani P, Ramoni MF, Nolan V, Baldwin CT, Steinberg MH. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet
2005;37(4):435-40.
12. Farrall M, Morris AP. Gearing up for genome-wide gene-association studies. Hum MoI Genet 2005;14 Spec No. 2:R157-62.
13. Verzilli CJ, Stallard N, Whittaker JC. Bayesian graphical models for genomewide association studies. Am J Hum Genet 2006;79(l): 100-12.
14. Colditz GA. The Nurses' Health Study: a cohort of US women followed since 1976. J Am Med Womens Assoc 1995;50(2):40-4.
15. Camargo CA, Jr., Weiss ST, Zhang S, Willett WC, Speizer FE. Prospective study of body mass index, weight change, and risk of adult-onset asthma in women. Arch Intern Med 1999; 159(21):2582-8.
16. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. . Am Rev Respir Dis 1987;136(l):225-44.
17. Baron RM, Palmer LJ, Tantisira K, et al. DNA sequence variants in epithelium- specific ETS-2 and ETS-3 are not associated with asthma. Am J Respir Crit Care Med 2002; 166(7):927-32.
18. Sonna L, Zhao L, Angel K, Cullivan M, Lilly C. US Army Research Institute of Environmental Medicine. Environmental Medicine Genome Bank Current Composition. USARIEM Technical Note TN00-8 July, 2000.
19. Lazarus R, Vercelli D, Palmer LJ, et al. Single nucleotide polymorphisms in innate immunity genes: abundant variation and potential role in complex human disease. Immunol Rev 2002; 190:9-25.
20. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001 ;68(4):978-89.
21. Sebastiani P, Lazarus R, Weiss ST, Kunkel LM, Kohane IS, Ramoni MF. Minimal haplotype tagging. Proc Natl Acad Sci U S A 2003;100(17):9900-5.
22. Cooper G, F. , Herskovits E. A Bayesian Method for the Induction of Probabilistic Networks from Data. Mach Learn 1992;9(4):309-47. 23. Barber CB, David PD, Hannu H. The quickhull algorithm for convex hulls. ACM Trans Math Softw 1996;22(4):469-83.
24. Fawcett T. ROC graphs: Notes and Practical Considerations for Researchers (HPL- 2003-4): HP Laboratories; 2003.
25. Rothenberg ME. Eotaxin. An essential mediator of eosinophil trafficking into mucosal tissues. Am J Respir Cell MoI Biol 1999;21(3):291-5.
26. Lamkhioued B, Renzi PM, Abi-Younes S, et al. Increased expression of eotaxin in bronchoalveolar lavage and airways of asthmatics contributes to the chemotaxis of eosinophils to the site of inflammation. J Immunol 1997;159(9):4593-601.
27. Lilly CM, Woodruff PG, Camargo CA, Jr., et al. Elevated plasma eotaxin levels in patients with acute asthma. J Allergy Clin Immunol 1999; 104(4 Pt 1 ):786-90.
28. Ying S, Robinson DS, Meng Q, et al. Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells. Eur J Immunol 1997;27(12):3507-16. 29. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004;303(5663): 1529-31.
30. Means TK, Golenbock DT, Fenton MJ. The biology of Toll-like receptors. Cytokine Growth Factor Rev 2000; 11(3):219-32.
31. Moisan J, Camateros P, Thuraisingam T, et al. TLR7 ligand prevents allergen- induced airway hyperresponsiveness and eosinophilia in allergic asthma by a MYD88-dependent and MK2-independent pathway. Am J Physiol Lung Cell MoI Physiol 2006;290(5):L987-95. 32. Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. Bmj 1993;307(6910):982-6.
33. Raby BA, Van Steen K, Lazarus R, Celedon JC, Silverman EK, Weiss ST. Eotaxin polymorphisms and serum total IgE levels in children with asthma. J Allergy Clin Immunol 2006;117(2):298-305. 34. Hakonarson H, Bjornsdottir US, Ostermann E, et al. Allelic frequencies and patterns of single-nucleotide polymorphisms in candidate genes for asthma and atopy in Iceland. Am J Respir Crit Care Med 2001;164(l l):2036-44.
35. Chae SC, Lee YC, Park YR, et al. Analysis of the polymorphisms in eotaxin gene family and their association with asthma, IgE, and eosinophil. Biochem Biophys Res Commun 2004;320(l): 131-7.
36. Shin HD, Kim LH, Park BL, et al. Association of Eotaxin gene family with asthma and serum total IgE. Hum MoI Genet 2003;12(l l):1279-85.
37. Miyamasu M, Sekiya T, Ohta K, et al. Variations in the human CC chemokine eotaxin gene. Genes Immun 2001;2(8):461-3. 38. Nakamura H, Luster AD, Nakamura T, et al. Variant eotaxin: its effects on the asthma phenotype. J Allergy Clin Immunol 2001 ;108(6):946-53.
39. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Effect of verification bias on screening for prostate cancer by measurement of prostate- specific antigen. N Engl J Med 2003;349(4):335-42. 40. Pisano ED, Gatsonis C, Hendrick E, et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 2005;353(17):1773- 83.
All references cited herein are fully incorporated by reference. Having now fully described the invention, it will be understood by those of skill in the art that the invention may be practiced within a wide and equivalent range of conditions, parameters and the like, without affecting the spirit or scope of the invention or any embodiment thereof.
Claims
1. A method of assessing if a subject is at high risk of developing asthma, comprising: a) determining the polymorphic form of at least three genes: i) the TLR7 gene (SEQ ID NO: 1 ); ii) the CCLl 1 gene (SEQ ID NO:3); and iii) the CCL2 gene (SEQ ID NO:5); b) correlating the frequency of combinations of polymorphic forms with the likelihood said subject is at high risk of developing asthma.
2. The method of claim 1, wherein it is concluded that said subject is at high risk of developing asthma if said subject: a) has a TLR7 gene with a sequence characterized by the single nucleotide polymorphism of: rsl79019 (SEQ ID NO:7); rsl79020 (SEQ ID NO:8); or rsl79017 (SEQ ID NO:9); b) has a CCLl 1 gene characterized by the single nucleotide polymorphism of: rsl 129844 (SEQ ID NO: 10); rsl7735961 (SEQ ID NO:11); rs4795895 (SEQ ID NO: 12); and c) has a CCL2 gene characterized by the single nucleotide polymorphism of rs4586 (SEQ ID NO: 13).
3. The method of claim 2, wherein said TLR7 gene is characterized by the single nucleotide polymorphism of: rsl79019 (SEQ ID NO:7).
4. The method of claim 2, wherein said TLR7 gene is characterized by the single nucleotide polymorphism of: rsl 79020 (SEQ ID NO:8).
5. The method of claim 2, wherein said TLR7 gene is characterized by the single nucleotide polymorphism of: rsl 79017 (SEQ ID NO:9).
6. The method of any one of claims 2-5, wherein said CCLl 1 gene is characterized by the single nucleotide polymorphism of: rsl 129844 (SEQ ID NO:10).
7. The method of any one of claims 2-5, wherein said CCLl 1 gene is characterized by the single nucleotide polymorphism of: rs 17735961 (SEQ ID NO:11).
8. The method of any one of claims 2-5, wherein said CCLl 1 gene is characterized by the single nucleotide polymorphism of: rs4795895 (SEQ ID NO: 12).
9. A method of assessing if a subject is at high risk of developing asthma, comprising: a) determining the amino acid sequence of at least three polypeptides: i) the TLR7 gene product (SEQ ID NO:2); ii) the CCLl 1 gene product (SEQ ID NO:4); and iii) the CCL2 gene product (SEQ ID NO:6); b) correlating the frequency of combinations of polymorphic forms of the proteins with the likelihood said subject is at high risk of developing asthma.
10. A DNA microarray for detecting the presence of SNPs indicative of a subject being at high risk of developing asthma, comprising oligonucleotides immobilized on a glass, plastic or nylon support, wherein said oligonucleotides are 20-500 nucleotides in length and wherein: a) at least one oligonucleotide has a sequence that matches exactly a corresponding sequence in SEQ ID NO:1 but in which one nucleotide in said corresponding sequence is replaced with a different nucleotide; b) at least one oligonucleotide has a sequence that matches exactly a corresponding sequence in SEQ ID NO:3 but in which one nucleotide in said corresponding sequence is replaced with a different nucleotide; and c) at least one oligonucleotide has a sequence that matches exactly a corresponding sequence in SEQ ID NO: 5 but in which one nucleotide in said corresponding sequence is replaced with a different nucleotide.
11. A DNA microarray for detecting the presence of SNPs indicative of a subject being at high risk of developing asthma, comprising oligonucleotides that are immobilized on a glass, plastic or nylon support, wherein said oligonucleotides are 20-250 nucleotides in length and wherein at least one oligonucleotide: a) has a sequence exactly matching a corresponding sequence in SEQ ID NO:7 and includes the single nucleotide polymorphism of rsl79019; b) has a sequence exactly matching a corresponding sequence in SEQ ID NO: 8 and includes the single nucleotide polymorphism of rs 179017; or c) has a sequence exactly matching a corresponding sequence in SEQ ID NO:9 and includes the single nucleotide polymorphism of rsl79017.
12. The DNA microarray of claim 1 1, further comprising at least one oligonucleotide that: a) has a sequence exactly matching a corresponding sequence in SEQ ID NO: 10 and includes the single nucleotide polymorphism of rsl 12944; b) has a sequence exactly matching a corresponding sequence in SEQ ID NO:11 and includes the single nucleotide polymorphism of rsl7735961; or c) has a sequence exactly matching a corresponding sequence in SEQ ID NO: 12 and includes the single nucleotide polymorphism of rs4795895.
13. The DNA microarray of either claim 11 or claim 12, further comprising an oligonucleotide exactly matching a corresponding sequence in SEQ ID NO: 13 and includes the single nucleotide polymorphism of rs4586.
14. A kit for amplifying nucleic acids using the polymerase chain reaction (PCR) comprising: a) an oligonucleotide primer at least 14 nucleotides in length and that has a sequence exactly matching a sequence in SEQ ID NO: 7 and which lies at least partially 5' to the single nucleotide polymorphism of rsl 79019 and a second oligonucleotide primer at least 14 nucleotides in length and that has a sequence exactly matching a sequence in SEQ ID NO: 7 and which lies at least partially 3' to the single nucleotide polymorphism of rsl 79019; b) an oligonucleotide primer at least 14 nucleotides in length and that has a sequence exactly matching a sequence in SEQ ID NO:8 and which lies at least partially 5' to the single nucleotide polymorphism of rsl 79020 and a second oligonucleotide primer at least 14 nucleotides in length and that has a sequence exactly matching a sequence in SEQ ID NO:8 and which lies at least partially 3' to the single nucleotide polymorphism of rsl79020; and/or
c) an oligonucleotide primer at least 14 nucleotides in length and that has a sequence exactly matching a sequence in SEQ ID NO:9 and which lies at least partially 51 to the single nucleotide polymorphism of rs 179017 and a second oligonucleotide primer at least 14 nucleotides in length and that has a sequence exactly matching a sequence in SEQ ID NO:9 and which lies at least partially 3' to the single nucleotide polymorphism of rs 179017.
15. The kit of claim 14, further comprising: a) an oligonucleotide primer at least 14 nucleotides in length and that has a sequence exactly matching a sequence in SEQ ID NO: 10 and which lies at least partially 5' to the single nucleotide polymorphism of rs 1129844 and a second oligonucleotide primer at least 14 nucleotides in length and that has a sequence exactly matching a sequence in SEQ ID NO: 10 and which lies at least partially 3' to the single nucleotide polymorphism of rsl 129844;
b) an oligonucleotide primer at least 14 nucleotides in length and that has a sequence exactly matching a sequence in SEQ ID NO: 11 and which lies at least partially 5' to the single nucleotide polymorphism of rsl 7735961 and a second oligonucleotide primer at least 14 nucleotides in length and that has a sequence exactly matching a sequence in SEQ ID NO: 11 and which lies at least partially 3' to the single nucleotide polymorphism of rsl 7735961; and/or
c) an oligonucleotide primer at least 14 nucleotides in length and that has a sequence exactly matching a sequence in SEQ ID NO: 12 and which lies at least partially 5' to the single nucleotide polymorphism of rs4795895 and a second oligonucleotide primer at least 14 nucleotides in length and that has a sequence exactly matching a sequence in SEQ ID NO: 12 and which lies at least partially 3' to the single nucleotide polymorphism of rs4795895.
16. The kit of either claim 14 or 15, further comprising an oligonucleotide primer at least 14 nucleotides in length and that has a sequence exactly matching a sequence in SEQ ID NO: 13 and which lies at least partially 5' to the single nucleotide polymorphism of rs4586 and a second oligonucleotide primer at least 14 nucleotides in length and that has a sequence exactly matching a sequence in SEQ ID NO: 13 and which lies at least partially 3' to the single nucleotide polymorphism of rs4586.
17. The method of either claim 1 or 2, wherein said polymorphic forms are detected by PCR amplification of nucleic acid derived from said subject followed by sequence analysis of the amplified DNA.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/448,949 US8357517B2 (en) | 2007-01-17 | 2008-01-16 | Genetic analyses predictive of asthma |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88070907P | 2007-01-17 | 2007-01-17 | |
US60/880,709 | 2007-01-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008088804A1 true WO2008088804A1 (en) | 2008-07-24 |
Family
ID=39636301
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/000524 WO2008088804A1 (en) | 2007-01-17 | 2008-01-16 | Genetic analyses predictive of asthma |
Country Status (2)
Country | Link |
---|---|
US (1) | US8357517B2 (en) |
WO (1) | WO2008088804A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018121468A1 (en) * | 2016-12-29 | 2018-07-05 | 安诺优达基因科技(北京)有限公司 | Method, device and kit for detecting fetal genetic mutation |
-
2008
- 2008-01-16 WO PCT/US2008/000524 patent/WO2008088804A1/en active Application Filing
- 2008-01-16 US US12/448,949 patent/US8357517B2/en not_active Expired - Fee Related
Non-Patent Citations (7)
Title |
---|
CHAE S.-C. ET AL.: "Analysis of the polymorphisms in eotaxin gene family and their association with asthma, IgE, and eosinophil", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 320, 2004, pages 131 - 137, XP004519075, DOI: doi:10.1016/j.bbrc.2004.05.136 * |
DATABASE GENBANK [online] 15 July 2006 (2006-07-15), accession no. NCBI Database accession no. (BC009716) * |
DATABASE GENBANK [online] 15 July 2006 (2006-07-15), accession no. NCBI Database accession no. (BC033651) * |
DATABASE GENBANK [online] 20 December 2003 (2003-12-20), accession no. NCBI Database accession no. (NM013654) * |
HYONG DOO SHIN ET AL.: "Association of Eotaxin gene family with asthma and serum total IgE", HUMAN MOLECULAR GENETICS, vol. 12, no. 11, 2001, pages 1279 - 1285 * |
KENT CHRISOPHERSON AND HROMAS R.: "Chemokine Regulation of Normal and Pathologic Immune Responses", STEM CELLS, vol. 19, 2001, pages 388 - 396, XP002606452 * |
MOISAN J. ET AL.: "TLR7 ligand prevents allergen-induced airway hyperresponsiveness and eosinophilis in allergic asthma by a MYD88-dependent and MK2-independent pathway", AM. J. PHYSIOL. LUNG CELL MOL. PHYSIOL., vol. 290, 2006, pages L987 - L995, XP008166092, DOI: doi:10.1152/ajplung.00440.2005 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018121468A1 (en) * | 2016-12-29 | 2018-07-05 | 安诺优达基因科技(北京)有限公司 | Method, device and kit for detecting fetal genetic mutation |
CN108277267A (en) * | 2016-12-29 | 2018-07-13 | 安诺优达基因科技(北京)有限公司 | Detect the device of gene mutation and the kit for carrying out parting to the genotype of pregnant woman and fetus |
CN108277267B (en) * | 2016-12-29 | 2019-08-13 | 安诺优达基因科技(北京)有限公司 | It detects the device of gene mutation and carries out the kit of parting for the genotype to pregnant woman and fetus |
Also Published As
Publication number | Publication date |
---|---|
US20090325811A1 (en) | 2009-12-31 |
US8357517B2 (en) | 2013-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20130096768A (en) | Markers for breast cancer | |
JP2008545390A (en) | Methods for assessing the risk of developing lung cancer using genetic polymorphism | |
Kim et al. | Gene-based copy number variation study reveals a microdeletion at 12q24 that influences height in the Korean population | |
CN116134152A (en) | Method for assessing risk of producing a severe response to coronavirus infection | |
Hsiao et al. | Epidemiological and genetic studies of myotonic dystrophy type 1 in Taiwan | |
US20160160279A1 (en) | Prognosis of response to treatment with anti-tnf-alpha in patients with rheumatoid arthritis | |
US6379890B1 (en) | Method for determining asthma susceptibility | |
US8168390B2 (en) | Method and apparatus for diagnosing age-related macular degeneration | |
US8357517B2 (en) | Genetic analyses predictive of asthma | |
WO2012018258A1 (en) | Markers of febrile seizures and temporal lobe epilepsy | |
KR20170013921A (en) | Dna methylation status as a biomarker of alcohol use and abstinence | |
KR20110034297A (en) | Marker for diagnosing intrinsic atopic dermatitis and use thereof | |
Wang et al. | Genetic variations in chemoattractant receptor expressed on Th2 cells (CRTH2) is associated with asthma susceptibility in Chinese children | |
JP7165099B2 (en) | Method for determining risk of myocardial infarction and/or angina pectoris | |
Maeda et al. | Genetic impact of functional single nucleotide polymorphisms in the 3′-UTR region of the chemoattractant receptor expressed on Th2 cells (CRTH2) gene on asthma and atopy in a Japanese population | |
US20190309366A1 (en) | CXR4 as a Susceptibility Locus in Juvenile Idiopathic Arthritis (JIA) and Methods of Use Thereof for the Treatment and Diagnosis of the Same | |
Li et al. | Lack of association between three promoter polymorphisms of PTGDR gene and asthma in a Chinese Han population | |
US7604945B2 (en) | Single nucleotide polymorphisms in protein-tyrosine phosphatase receptor-type delta for the diagnosis of susceptibility to asthma | |
CN104774840A (en) | Gene mutant and applications thereof | |
WO2014121180A1 (en) | Genetic variants in interstitial lung disease subjects | |
US20110177963A1 (en) | Variation in the CHI3L1 Gene Influences Serum YKL-40 Levels, Asthma Risk and Lung Function | |
WO2009103992A1 (en) | Genetic variation associated with coeliac disease | |
JP7161440B2 (en) | How to determine the risk of bronchial asthma | |
JP5111763B2 (en) | Genetic predisposition test for bronchial asthma | |
JP2023552199A (en) | Methods for identifying subjects at high risk of developing coronavirus infection and methods for treatment thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08724531 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12448949 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08724531 Country of ref document: EP Kind code of ref document: A1 |